Aphea.Bio has struck a strategic research partnership with Bayer to co-develop bioinsecticides targeting sap-sucking insects, in a move that underscores the broader shift among agrochemical majors toward biological crop protection.
The collaboration will combine Aphea.Bio’s pipeline of bioactive metabolites – derived from carefully screened microbial strains – with Bayer’s global development, regulatory and commercialisation capabilities. The initial focus is on fruit crops including pome, stone fruit, citrus and grapes, with scope to expand into vegetables and major row crops such as cotton and soybean.
“The bioinsecticide market has been waiting for a partnership like this,” said Aphea.Bio CEO Isabel Vercauteren. “Together, we can deliver crop protection that actually works on a global scale.”
Bayer said the agreement will help “broaden the crop protection toolbox” and accelerate scalable biological solutions for growers.
A wider industry shift gathers pace
The deal is the latest signal that the largest ag input companies – including Bayer, Syngenta, BASF and Corteva – are materially increasing investment in agricultural biologicals, marking a structural shift in crop protection strategy.
Across the sector, companies are ramping up R&D partnerships with biotech firms, acquisitions of biologicals specialists, dedicated manufacturing capacity and new product launches, particularly in biopesticides.
Industry-wide strategies now position biologicals as a core growth engine, rather than a niche adjunct to conventional chemistry.
Bioinsecticides move into the spotlight
Bioinsecticides – products derived from microbes or natural compounds – are emerging as one of the most strategically important categories within biologicals.
Sap-sucking insects, the initial target of the Bayer-Aphea partnership, represent a major global threat to crop yields, while resistance to conventional insecticides and tighter regulation are eroding the effectiveness of legacy solutions.
Aphea.Bio’s approach centres on microbial metabolites that combine the environmental profile of biologicals with the stability and usability of conventional products – a key barrier the industry has long sought to overcome as major players are pushing toward integrated systems combining biologicals and conventional inputs.
The companies will jointly advance candidates through field validation and early regulatory work, with milestone gates tied to efficacy, safety and manufacturability.
Bayer’s strategy shaped – but not defined – by litigation
The partnership also comes as Bayer continues to navigate extensive litigation linked to its Roundup weedkiller.
The company faces around 100,000 claims alleging glyphosate causes cancer and has already spent billions on settlements. CEO Bill Anderson has warned that failure to resolve the issue could jeopardise U.S. glyphosate production, while Bayer pursues a mix of legal appeals, settlements and lobbying efforts to contain liability.
Despite speculation, Bayer has said it has no immediate plans to restructure or spin off Monsanto, instead focusing on performance improvements and litigation management.
While Bayer’s push into biologicals is not a direct response to the legal challenges, the financial and strategic pressure has sharpened its focus on diversifying into lower-risk, next-generation crop protection technologies.
